Implications of IDH mutations on immunotherapeutic strategies for malignant glioma

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

(2021) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

(2021) Nathan D. Mathewson et al.   CELL

A vaccine targeting mutant IDH1 in newly diagnosed glioma

(2021) Michael Platten et al.   NATURE

The immune landscape of common CNS malignancies: implications for immunotherapy

(2021) Martina Ott et al.   Nature Reviews Clinical Oncology

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

(2020) Sue Han et al.   BRITISH JOURNAL OF CANCER

Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes

(2020) Ekaterina Friebel et al.   CELL

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

(2020) Florian Klemm et al.   CELL

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells

(2020) Hiroaki Nagashima et al.   Cancer Discovery

What is the burden of proof for tumor mutational burden in gliomas?

(2020) Mustafa Khasraw et al.   NEURO-ONCOLOGY

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

(2020) Padma Kadiyala et al.   JOURNAL OF CLINICAL INVESTIGATION

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas

(2019) Leland G. Richardson et al.   Translational Cancer Research

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

(2019) Lizza E.L. Hendriks et al.   Journal of Thoracic Oncology

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

Longitudinal molecular trajectories of diffuse glioma in adults

(2019) Floris P. Barthel et al.   NATURE

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

(2018) Lukas Bunse et al.   NATURE MEDICINE

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

(2018) Patrick Danaher et al.   Journal for ImmunoTherapy of Cancer

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant IDH1 regulates the tumor-associated immune system in gliomas

(2017) Nduka M. Amankulor et al.   GENES & DEVELOPMENT

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

(2017) Gary Kohanbash et al.   JOURNAL OF CLINICAL INVESTIGATION

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

The role of microglia and macrophages in glioma maintenance and progression

(2016) Dolores Hambardzumyan et al.   NATURE NEUROSCIENCE

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

(2016) Xiaoran Zhang et al.   NEURO-ONCOLOGY

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE